Myelofibrosis (MF) is a rare type of cancer that affects the bone marrow. Bone marrow is a spongy area in the center of your bones. When there are cancer cells in the bone marrow, your body has a hard time making healthy blood cells. “Myelo” means your spinal cord, where your bone marrow is. “Fibrosis” means scarring. The bone marrow fills with scar tissue (fibrosis).
MF may also be called primary myelofibrosis, chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, or agnogenic myeloid metaplasia.
If your provider thinks you may have myelofibrosis, they may order tests, like a bone marrow biopsy to look at your blood cells and molecular testing to look for gene mutations (changes) in the JAK2, CALR, and MPL genes.
Myelofibrosis is not staged like other cancers. You must meet certain criteria to be diagnosed with myelofibrosis. The World Health Organization (WHO) has made criteria for diagnosing MF. You must meet all 3 major criteria and 1 minor criterion for diagnosis. The criteria for MF can be complex and hard to understand. Your provider will go over any of the criteria listed below that you may have:
Treatment for MF depends on your symptoms, your age, and your overall health. Treatment may be:
The goals of supportive care are to:
Supportive care treatments may be:
Targeted therapy is medications that target the specific genes in MF. Ruxolitinib is currently the only medication with FDA approval for the treatment of MF. Ruxolitinib is a kinase inhibitor. A kinase inhibitor blocks an enzyme (protein) called a kinase. It helps treat MF by stopping cancer cells from multiplying. Other medications in this class are being studied in clinical trials.
Lenalidomide and thalidomide are immunomodulators and are also used in the treatment of myelofibrosis.
Interferon is an immune therapy that works by lowering the amount of unhealthy blood cells and reducing the cytokines that cause scarring (fibrosis) in the marrow. It seems to work best in those with early myelofibrosis secondary to PV or ET. Interferon has side effects that can be hard to manage.
The only treatment that can cure myelofibrosis is an allogeneic stem cell transplant (where the bone marrow comes from a donor). Stem cell transplants can lead to serious side effects. For this reason, they are often only done if you are in good health, if you are younger than 60, and if you have a "matched" donor. Stem cell transplants are only done in young patients with high-risk disease.
You may be offered a clinical trial as part of your treatment plan. To find out more about current clinical trials, visit the OncoLink Clinical Trials Matching Service.
Your care team will make sure you are a part of choosing your treatment plan. This can be overwhelming as you may be given a few options to choose from. It feels like an emergency, but you can take a few weeks to meet with different providers and think about your options and what is best for you. This is a personal decision. Friends and family can help you talk through the options and the pros and cons of each, but they cannot make the decision for you. You need to be comfortable with your decision – this will help you move on to the next steps. If you ever have any questions or concerns, be sure to call your team.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2025 Trustees of The University of Pennsylvania